Form 4: ProMIS Neurosciences Director Boosts Stake with Warrant Exercises

A ProMIS Neurosciences Inc. director and 10% owner significantly increased beneficial ownership through warrant exercises and new warrant acquisition.

Summary

• Jeremy M. Sclar, a Director and 10% owner of ProMIS Neurosciences Inc., reported significant changes in his beneficial ownership through associated trusts and entities.
• On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (JS Trust) exercised 697,674 Tranche A, 697,674 Tranche B, and 697,674 Tranche C purchase warrants, totaling 2,093,022 common shares.
• The original exercise prices for Tranche A and B warrants were $2.02 per share, and for Tranche C warrants was $2.50 per share.
• Following an offer by the JS Trust and acceptance by the Issuer, all these warrants were exercised at a reduced price of $0.83518 per share.
• On July 29, 2025, the JS Trust acquired a new warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share.
• The purchase price for this new warrant was $0.1875 per Common Share underlying the warrant.
• The new warrant is currently exercisable and expires five years after its issuance date.
• Following these transactions, Sclar's indirect beneficial ownership through the JS Trust increased to 3,710,459 common shares, in addition to 1,155,726 shares held through Crocker Mountain LLC and 65,000 shares held directly.

Sentiment

Score: 6

Explanation: While the significant insider investment and capital infusion are positive, the substantial reduction in warrant exercise prices suggests the company needed to incentivize the capital raise, which is a negative for existing shareholders in terms of dilution value. The new warrant provides future capital potential.

Positives

• A Director and 10% owner, Jeremy M. Sclar, demonstrated significant insider commitment by exercising warrants and acquiring new ones, signaling confidence in the company.
• The company received approximately $1.75 million from the exercise of 2,093,022 Tranche A, B, and C warrants at $0.83518 per share.
• The company received approximately $0.59 million from the purchase of the new warrant for 3,139,533 common shares at $0.1875 per underlying share.
• The newly acquired warrant provides potential for future capital infusion of approximately $3.92 million if fully exercised at $1.25 per share.

Negatives

• The company accepted a significantly reduced exercise price of $0.83518 per share for Tranche A, B, and C warrants, down from original prices of $2.02 and $2.50, which implies a less favorable capital raise and greater dilution for existing shareholders than initially planned.

Future Outlook

The acquisition of a new warrant, exercisable for five years, indicates a potential future capital infusion for the company, contingent on its exercise by the Jeremy M. Sclar 2012 Irrevocable Family Trust.

Industry Context

This Form 4 filing is a specific disclosure of insider trading activity and does not provide broader industry context or trends.

Related Party Transactions

• The transactions involve Jeremy M. Sclar, a Director and 10% owner, and entities he controls (Jeremy M. Sclar 2012 Irrevocable Family Trust and Crocker Mountain LLC), making them related-party transactions.

Stakeholder Impact

• Shareholders: Experienced dilution from the warrant exercises at a significantly reduced price compared to original terms. However, increased insider ownership may be viewed as a positive signal of confidence.
• Company: Received capital from the warrant exercises and the purchase of the new warrant, which can strengthen its financial position and support operations.

Next Steps

• Potential future exercise of the newly acquired warrant by the Jeremy M. Sclar 2012 Irrevocable Family Trust within its five-year expiry period.

Key Dates

Recommendation

The filing indicates a significant capital infusion and continued insider commitment, which are generally positive. However, the substantial reduction in warrant exercise prices suggests a less favorable capital raise for the company, potentially diluting existing shareholders at a lower value than initially planned. This mixed signal warrants a 'hold' as investors assess the company's underlying performance and future capital needs.

Keywords

ProMIS Neurosciences, PMN, Insider Trading, Form 4, Warrant Exercise, Beneficial Ownership, Capital Raise, Biotechnology, Neuroscience